Icosavax Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
59
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.14B
- Investors
-
1
Icosavax General Information
Description
Developer of computationally designed virus-like particle vaccine designed to reduce serious infectious diseases including respiratory syncytial virus. The company's VLP platform technology is designed to enable a multivalent, particle-based display of complex viral antigens, that induce broad, robust and durable protection against the specific viruses targeted.
Contact Information
Website
www.icosavax.comCorporate Office
- 1930 Boren Avenue
- Suite 1000
- Seattle, WA 98101
- United States
Corporate Office
- 1930 Boren Avenue
- Suite 1000
- Seattle, WA 98101
- United States
Icosavax Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 19-Feb-2024 | $1.14B | Completed | Generating Revenue | ||
| 8. PIPE | 11-Aug-2023 | Completed | Generating Revenue | |||
| 7. IPO | 29-Jul-2021 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series B) | 07-Apr-2021 | Completed | Generating Revenue | |||
| 5. Grant | 02-Nov-2020 | Completed | Startup | |||
| 4. Early Stage VC (Series A) | 03-Oct-2019 | Completed | Startup | |||
| 3. Seed Round | 01-Jan-2018 | Completed | Startup | |||
| 2. Grant | Completed | Startup | ||||
| 1. University Spin-Out | 01-Jan-2017 | Completed | Startup |
Icosavax Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A-2 | 4,949,794 | $0.000100 | 8% | $0.77 | $0.77 | 1x | $0.77 | 3.99% |
| Series A-1 | 49,193,959 | $0.000100 | 8% | $0.96 | $0.96 | 1x | $0.96 | 39.69% |
Icosavax Comparisons
Industry
Financing
Details
Icosavax Competitors (12)
One of Icosavax’s 12 competitors is VLPbio, a Formerly VC-backed company based in Boecillo, Spain.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| VLPbio | Formerly VC-backed | Boecillo, Spain | ||||
| MnPharm | Venture Capital-Backed | White Bear Lake, MN | ||||
| OyaGen | Venture Capital-Backed | Rochester, NY | ||||
| iBio | Corporation | San Diego, CA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE |
Icosavax Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Icosavax Patents
Icosavax Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250222092-A1 | Protein nanostructure vaccine | Pending | 09-Jan-2024 | ||
| WO-2025151358-A1 | Protein nanostructure vaccine | Inactive | 09-Jan-2024 | ||
| EP-4812180-A1 | Nanostructure-forming polypeptides and uses thereof | Pending | 21-Nov-2023 | ||
| US-20250163400-A1 | Nanostructure-forming polypeptides and uses thereof | Pending | 21-Nov-2023 | ||
| WO-2025111362-A1 | Nanostructure-forming polypeptides and uses thereof | Inactive | 21-Nov-2023 | C12Y401/02014 |
Icosavax Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Icosavax Former Investors (27)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Adams Street Partners | PE/Buyout | Minority | ||
| Burroughs Wellcome Fund | Other | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority | ||
| Embo (Other Commercial Services) | Other | Minority | ||
| Gates Foundation | Not-For-Profit Venture Capital | Minority |
Icosavax ESG
Risk Overview
Risk Rating
Updated August, 31, 2023
33.34 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Pharmaceuticals
Subindustry
of 435
Rank
Percentile
Icosavax FAQs
-
When was Icosavax founded?
Icosavax was founded in 2017.
-
Where is Icosavax headquartered?
Icosavax is headquartered in Seattle, WA.
-
What is the size of Icosavax?
Icosavax has 59 total employees.
-
What industry is Icosavax in?
Icosavax’s primary industry is Drug Discovery.
-
Is Icosavax a private or public company?
Icosavax is a Private company.
-
What is the current valuation of Icosavax?
The current valuation of Icosavax is .
-
What is Icosavax’s current revenue?
The current revenue for Icosavax is .
-
How much funding has Icosavax raised over time?
Icosavax has raised $405M.
-
Who are Icosavax’s investors?
Adams Street Partners, Burroughs Wellcome Fund, Cormorant Asset Management, Embo (Other Commercial Services), and Gates Foundation are 5 of 27 investors who have invested in Icosavax.
-
Who are Icosavax’s competitors?
VLPbio, MnPharm, OyaGen, iBio, and Ayala Pharmaceuticals are some of the 12 competitors of Icosavax.
-
When was Icosavax acquired?
Icosavax was acquired on 19-Feb-2024.
-
Who acquired Icosavax?
Icosavax was acquired by AstraZeneca.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
